New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

134.90 2.16 +1.63%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Merck & Co., Inc. 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:14 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 7, 2026: 10 added · 8 removed · 79 modified; 8 with only figures updated; 3 moved without change

  1. Added · Business Development Transactions

    In September 2026, Merck and SciBrunch Therapeutics Co., Ltd. (SciBrunch) closed an exclusive license agreement for MK-2690 (SPR2015), a potent and selective novel, investigational, preclinical, molecular glue KRAS G12D (ON) inhibitor, targeting cancers and tumors characterized by the KRAS G12D mutation. Under the agreement, SciBrunch granted Merck exclusive rights to develop, manufacture and commercialize MK-2690 (SPR2015) worldwide. The Company recorded a charge to Research and development expenses of $400 million in the third quarter and first nine months of 2026, or $0.12 per share, for the upfront payment, which is expected to be paid in the fourth quarter of 2026. SciBrunch is also eligible to receive future contingent development-related, regulatory, and, if approved, sales-based milestone payments.